McKesson shares the goal of addressing rising healthcare costs for Americans. We are committed to bolstering community providers, which are often the lower cost, preferred setting of care for patients. We are committed to supporting safety net providers and recognize the critical role they play in our healthcare ecosystem.
We continue to invest in provider and patient tools to drive cost transparency and enable data-driven, shared decision-making between providers and patients. We recognize the need to improve efficiency in our health care system while reducing patient financial toxicity, but we believe that proposals must not jeopardize patient access and risk further erosion of community and safety net providers for short term savings. We encourage lawmakers to think about drug pricing in the context of the total cost of patient care.
Leveraging 340B drug discounts for vulnerable patients
At McKesson, we recognize the vital role the 340B drug discount program plays in helping healthcare providers stretch scarce federal resources to service patients in need. We understand the need for increased transparency and accountability to ensure the 340B program benefits patients.
We recommend a thoughtful and inclusive approach to 340B program reforms to ensure that changes do not disrupt care and services for vulnerable patients.